Aditxt, Inc. Business Combination, Acquisition Related Costs
Aditxt, Inc. (ADTX) reported Business Combination, Acquisition Related Costs of $1.01 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2025-03-31
- Aditxt, Inc. business combination, acquisition related costs for the quarter ending 2024-12-31 was $0.00.
- Aditxt, Inc. business combination, acquisition related costs for the quarter ending 2024-09-30 was $0.00.
- Aditxt, Inc. business combination, acquisition related costs for the quarter ending 2024-06-30 was $0.00.
- Aditxt, Inc. business combination, acquisition related costs for the quarter ending 2024-03-31 was $1.01M.
- Aditxt, Inc. business combination, acquisition related costs for fiscal 2024 was $1.01M.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $1.01M 10-K · filed 2025-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | $0.00 derived: sum of 2 quarters · filed 2024-11-18 | $1.01M 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-19 | $1.01M 10-Q · filed 2024-08-19 | ||
| 2024-03-31 | $1.01M 10-Q · filed 2024-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |